Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UX007 in glucose transporter type 1 deficiency syndrome
2013-003771-35Phase 2Completed
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Glucose Transporter Type 1 Deficiency Syndrome (Glut1DS) comparing Triheptanoin with Placebo (2 arms). Primary endpoint: Reduction from baseline in monthly frequency of generalized or partial-onset seizures between Weeks 2 and 8. Started Dec 2013; status: completed.
02
Drugs
triheptanoin
03
Conditions
Glucose Transporter Type 1 Deficiency Syndrome (Glut1DS)
Beyond the preview
Go deeper on 2013-003771-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003771-35.